SCHEMBL120182

SCHEMBL120182

CC(C)N1Cc2ccccc2C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.57
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 1/20 0.57
TSHR P16473 1/20 0.57
XIAP P98170 1/20 0.57
HKDC1 Q2TB90 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
KMT2A Q03164 5/20 0.57
THRB P10828 3/20 0.56
MEN1 O00255 4/20 0.55
SDCBP O00560 2/20 0.54
SDC2 P34741 2/20 0.54
MAPT P10636 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658619 0.85 ALOX15 (0.58) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL24834797 0.85 SDCBP (0.55) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL23867096 0.85 SDCBP (0.55) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL22997450 0.85 SDCBP (0.55) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL24369039 0.82 KMT2A (0.54) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL21473595 0.82 ALOX15 (0.63) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL1585291 0.82 ALOX15 (0.63) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL24369040 0.82 KMT2A (0.54) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL24369041 0.82 KMT2A (0.54) ALOX15KDM4EALDH1A1TSHRXIAP
SCHEMBL31252800 0.82 KMT2A (0.54) ALOX15KDM4EALDH1A1TSHRXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
US-12037344-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2024-07-16 US disclosed
US-12037344-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2024-07-16 US disclosed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
WO-2024124464-A1 INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING 武汉睿健医药科技有限公司 2024-06-20 WO disclosed
WO-2024124463-A1 PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 武汉睿健医药科技有限公司 2024-06-20 WO disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 WO disclosed
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 US disclosed
US-20080317712-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-12-25 US disclosed
US-20080279821-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-11-13 US disclosed
WO-2008054749-A1 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2008-05-08 WO disclosed
US-20070276042-A1 PREPARATION AND UTILITY OF SUBSTITUTED CARBOXYLIC ACID COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-20070276042-A1 PREPARATION AND UTILITY OF SUBSTITUTED CARBOXYLIC ACID COMPOUNDS AUSPEX PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 ALOX15 3717/4885KDM4E 4298/4885ALDH1A1 4342/4885
US-20080279821-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS PRSS1, CTSC, SPINT2 ALOX15 2864/4885KDM4E 1120/4885ALDH1A1 691/4885
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 ALOX15 2183/4885KDM4E 2587/4885ALDH1A1 2440/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN ALOX15 4805/4885KDM4E 1112/4885ALDH1A1 3804/4885
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 ALOX15 4514/4885KDM4E 1450/4885ALDH1A1 2211/4885
US-12037344-B2 NLRP3 modulators NLRP3, NLRP1, PYCARD ALOX15 267/4885KDM4E 3888/4885ALDH1A1 843/4885
US-20070276042-A1 PREPARATION AND UTILITY OF SUBSTITUTED CARBOXYLIC ACID COMPOUNDS PTGES, HTRA1, PYGM ALOX15 15/4885KDM4E 3185/4885ALDH1A1 993/4885
US-20080317712-A1 ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS PREP, DNPEP, CTSC ALOX15 3242/4885KDM4E 1403/4885ALDH1A1 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.